BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

549 related articles for article (PubMed ID: 27191652)

  • 1. Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer.
    Zheng H; Liu X; Zhang J; Rice SJ; Wagman M; Kong Y; Zhu L; Zhu J; Joshi M; Belani CP
    Oncotarget; 2016 Aug; 7(35):56233-56240. PubMed ID: 27191652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review.
    Brody R; Zhang Y; Ballas M; Siddiqui MK; Gupta P; Barker C; Midha A; Walker J
    Lung Cancer; 2017 Oct; 112():200-215. PubMed ID: 29191596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients.
    Takada K; Toyokawa G; Okamoto T; Shimokawa M; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Oda Y; Maehara Y
    Clin Lung Cancer; 2017 Sep; 18(5):572-582.e1. PubMed ID: 28318951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach.
    Paulsen EE; Kilvaer TK; Khanehkenari MR; Al-Saad S; Hald SM; Andersen S; Richardsen E; Ness N; Busund LT; Bremnes RM; Donnem T
    Clin Lung Cancer; 2017 Mar; 18(2):220-233.e8. PubMed ID: 27816392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer.
    Shien K; Papadimitrakopoulou VA; Wistuba II
    Lung Cancer; 2016 Sep; 99():79-87. PubMed ID: 27565919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Programmed death-ligand 1 expression and T790M status in EGFR-mutant non-small cell lung cancer.
    Hata A; Katakami N; Nanjo S; Okuda C; Kaji R; Masago K; Fujita S; Yoshida H; Zama K; Imai Y; Hirata Y
    Lung Cancer; 2017 Sep; 111():182-189. PubMed ID: 28838391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Distribution and Clinical Significance of CTLA-4, PD-1 and PD-L1 in Peripheral Blood of Patients with Small Cell Lung Cancer].
    Li H; Liu Y; Liu Y; Liu J; Zhao D; Wang Y; Cheng Y
    Zhongguo Fei Ai Za Zhi; 2017 Nov; 20(11):755-760. PubMed ID: 29167005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC).
    Incorvaia L; Fanale D; Badalamenti G; Barraco N; Bono M; Corsini LR; Galvano A; Gristina V; Listì A; Vieni S; Gori S; Bazan V; Russo A
    Adv Ther; 2019 Oct; 36(10):2600-2617. PubMed ID: 31432460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Progress of PD-1/PD-L1 Inhibitors in Non-small Cell Lung Cancer].
    Jiang Z; Pan Z; Ren X
    Zhongguo Fei Ai Za Zhi; 2017 Feb; 20(2):138-142. PubMed ID: 28228226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
    Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y
    Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients.
    Nomizo T; Ozasa H; Tsuji T; Funazo T; Yasuda Y; Yoshida H; Yagi Y; Sakamori Y; Nagai H; Hirai T; Kim YH
    Sci Rep; 2017 Mar; 7():45124. PubMed ID: 28332580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers].
    Duruisseaux M; Rouquette I; Adam J; Cortot A; Cazes A; Gibault L; Damotte D; Lantuejoul S
    Ann Pathol; 2017 Feb; 37(1):61-78. PubMed ID: 28162296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durvalumab in non-small-cell lung cancer patients: current developments.
    Mezquita L; Planchard D
    Future Oncol; 2018 Feb; 14(3):205-222. PubMed ID: 29140105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages.
    Vieira T; Antoine M; Hamard C; Fallet V; Duruisseaux M; Rabbe N; Rodenas A; Cadranel J; Wislez M
    Lung Cancer; 2016 Aug; 98():51-58. PubMed ID: 27393506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alteration of PD-L1 expression and its prognostic impact after concurrent chemoradiation therapy in non-small cell lung cancer patients.
    Fujimoto D; Uehara K; Sato Y; Sakanoue I; Ito M; Teraoka S; Nagata K; Nakagawa A; Kosaka Y; Otsuka K; Imai Y; Hamakawa H; Takahashi Y; Kokubo M; Tomii K
    Sci Rep; 2017 Sep; 7(1):11373. PubMed ID: 28900290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 on peripheral blood T lymphocytes is prognostic in patients with non-small cell lung cancer (NSCLC) treated with EGFR inhibitors.
    Meniawy TM; Lake RA; McDonnell AM; Millward MJ; Nowak AK
    Lung Cancer; 2016 Mar; 93():9-16. PubMed ID: 26898608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.
    Schmidt LH; Kümmel A; Görlich D; Mohr M; Bröckling S; Mikesch JH; Grünewald I; Marra A; Schultheis AM; Wardelmann E; Müller-Tidow C; Spieker T; Schliemann C; Berdel WE; Wiewrodt R; Hartmann W
    PLoS One; 2015; 10(8):e0136023. PubMed ID: 26313362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval.
    Khozin S; Abernethy AP; Nussbaum NC; Zhi J; Curtis MD; Tucker M; Lee SE; Light DE; Gossai A; Sorg RA; Torres AZ; Patel P; Blumenthal GM; Pazdur R
    Oncologist; 2018 Mar; 23(3):328-336. PubMed ID: 29317551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab.
    Nicolazzo C; Raimondi C; Mancini M; Caponnetto S; Gradilone A; Gandini O; Mastromartino M; Del Bene G; Prete A; Longo F; Cortesi E; Gazzaniga P
    Sci Rep; 2016 Aug; 6():31726. PubMed ID: 27553175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.